Scarica l'app Stockscreener
19.78
1.30%
-0.26
Dopo l'orario di chiusura:
19.78
Precedente Chiudi:
$20.04
Aprire:
$20.45
Volume 24 ore:
566.77K
Relative Volume:
1.22
Capitalizzazione di mercato:
$690.17M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-1.69%
1M Prestazione:
+19.16%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$18.70
$20.95
Intervallo di 1 settimana:
$17.59
$20.95
Portata 52W:
$14.72
$25.58
First Tracks Biotherapeutics Inc Stock (TRAX) Company Profile
Nome
First Tracks Biotherapeutics Inc
Settore
Industria
Telefono
212-373-3000
Indirizzo
10770 WATERIDGE CIRCLE, SAN DIEGO
Compare TRAX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TRAX
First Tracks Biotherapeutics Inc
|
19.78 | 699.24M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
First Tracks Biotherapeutics Inc Stock (TRAX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-24 | Iniziato | Leerink Partners | Outperform |
| 2026-04-24 | Iniziato | Wedbush | Outperform |
| 2026-04-23 | Iniziato | JP Morgan | Overweight |
| 2026-04-22 | Iniziato | Barclays | Overweight |
| 2026-04-21 | Iniziato | UBS | Buy |
First Tracks Biotherapeutics Inc Borsa (TRAX) Ultime notizie
Is AnaptysBio’s (ANAB) Index Exit and Office Sublease Quietly Reframing Its Strategic Focus? - simplywall.st
First Tracks Biotherapeutics, Inc.(NasdaqGS:TRAX) added to Russell Microcap Value Benchmark Index - marketscreener.com
First Tracks Biotherapeutics, Inc.(NasdaqGS:TRAX) added to Russell 2000 Value Benchmark - marketscreener.com
First Tracks Biotherapeutics, Inc.(NasdaqGS:TRAX) added to Russell 2500 Value Benchmark - marketscreener.com
TRAX Forecast — Price Target — Prediction for 2027 - TradingView
The Nasdaq Biotechnology Index closed up more than 1.52%. Among its constituents, Absci surged 35.96%, Silence Therapeutics rose 26.00%, and Aardvark Therapeutics, Definium Therapeutics, Black Diamond, Personalis, and Adaptive Biotechnologies gai - Bitget
AnaptysBio Subleases San Diego Facility to First Tracks - TipRanks
First Tracks Biotherapeutics (NASDAQ: TRAX) subleases 45,057 sq ft in San Diego - Stock Titan
AnaptysBio (NASDAQ: ANAB) subleases San Diego facility to First Tracks under master lease - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
TRAX Price Today: First Tracks Biotherapeutics, Inc. Stock Price, Quote & Chart | MEXC - mexc.co
TRAX SEC FilingsFirst Tracks Biotherapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
First Tracks Biotherapeutics Ord Shs (TRAX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Rita Jain of First Tracks Biotherapeutics (TRAX) exercises RSUs, lifts holdings to 19,194 shares - Stock Titan
First Tracks Biotherapeutics (TRAX) director settles 6,030 RSUs into shares - Stock Titan
[Form 4] First Tracks Biotherapeutics, Inc. Insider Trading Activity - Stock Titan
First Tracks Biotherapeutics (TRAX) director converts 6,030 RSUs into common shares - Stock Titan
Magda Marquet at First Tracks Biotherapeutics (TRAX) settles 6,030 RSUs - Stock Titan
First Tracks Biotherapeutics (TRAX) director converts 6,030 RSUs into common stock - Stock Titan
[Form 4/A] First Tracks Biotherapeutics, Inc. Amended Insider Trading Activity - Stock Titan
First Tracks Biotherapeutics (TRAX) director receives stock options and RSU grant - Stock Titan
First Tracks Biotherapeutics (TRAX) awards options and RSUs to director - Stock Titan
Director at First Tracks Biotherapeutics (TRAX) gets equity awards - Stock Titan
First Tracks Biotherapeutics (TRAX) director awarded options and RSUs - Stock Titan
H.C. Wainwright initiates AnaptysBio stock coverage with buy rating - Investing.com UK
H.C. Wainwright initiates AnaptysBio stock coverage with buy rating By Investing.com - Investing.com Canada
TRAX Initiated Coverage by First Tracks -- Rating Set to Overwei - GuruFocus
Wells Fargo Initiates First Tracks Biotherapeutics at Overweight - Moomoo
AnaptysBio earnings up next: First report as royalty company - Investing.com
MNPR Stock Price and Chart — NASDAQ:MNPR - TradingView
TRAXFirst Tracks Biotherapeutics Inc Stock Price and Quote - Finviz
AnaptysBio Details Tax Treatment of Spin-Off Dividend - TipRanks
Spin-off dividend tax info posted by AnaptysBio (NASDAQ: ANAB) - Stock Titan
First Tracks Biotherapeutics (TRAX) Stock Price, News & Analysis $TRAX - MarketBeat
J.P. Morgan Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Cuts Target Price to $30 - Moomoo
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences - Sahm
Zumiez Inc. to Report Fiscal 2026 First Quarter Results - The Manila Times
First Tracks Biotherapeutics (TRAX) Stock Forecast and Price Target 2026 $TRAX - MarketBeat
TRAXV SEC FilingsFirst Tracks Biotherapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
First Tracks Biotherapeutics, Inc.Ordinary Shares (NQ: TRAX - FinancialContent
AnaptysBio (ANAB) Valuation After Spin Off And Shift To Royalty Focused Model - Sahm
First Tracks Biotherapeutics (NASDAQ: TRAX) registers 10.5M resale shares; issuer gets no proceeds - Stock Titan
Emily Bodnar Reiterates Buy on AnaptysBio, Keeps $30 Price Target on ANB033 Progress and Solid Cash Runway - TipRanks
How The Grupo Traxión (BMV:TRAXION A) Story Is Shifting With Cautious New Analyst Targets - Yahoo Finance
Form 424B3 First Tracks Biotherapeu - StreetInsider
First Tracks Biotherapeutics (NASDAQ: TRAX) registers 10.5M resale shares - Stock Titan
First Tracks Biotherapeutics 1Q 2026: Net loss $(50.5M), Revenue $0— 10-Q Summary - TradingView
First Tracks Biotherapeutics (NASDAQ: TRAX) details Q1 loss and major post spin-off cash raises - Stock Titan
First Tracks Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
[8-K] First Tracks Biotherapeutics, Inc. Reports Material Event - Stock Titan
First Tracks Biotherapeutics Inc Azioni (TRAX) Dati Finanziari
Non sono disponibili dati finanziari per First Tracks Biotherapeutics Inc (TRAX). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
First Tracks Biotherapeutics Inc Azioni (TRAX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Schmid John P. | Director |
Jun 15 '26 |
Option Exercise |
0.00 |
6,030 |
0 |
37,652 |
| Orwin John A | Director |
Jun 15 '26 |
Option Exercise |
0.00 |
6,030 |
0 |
16,695 |
| Ware J. Anthony | Director |
Jun 15 '26 |
Option Exercise |
0.00 |
6,030 |
0 |
15,660 |
| Marquet Magda | Director |
Jun 15 '26 |
Option Exercise |
0.00 |
6,030 |
0 |
15,960 |
| FENTON DENNIS M | Director |
Jun 15 '26 |
Option Exercise |
0.00 |
6,030 |
0 |
10,995 |
1.17%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):